Table 2.
Adjusted and unadjusted odds ratios with ESBL-EC bacteraemia as the dependent variable
| ESBL-EC (%) | ESBL-KP (%) | Crude OR (95% CI) d /P value | Adjusted OR (95% CI) d | |
|---|---|---|---|---|
|
Demographics/acquisition | ||||
| Male gendera |
60/92 (65.2) |
49/78 (62.8) |
1.1 (0.6–2.2) |
|
| Median age (IQR)a |
65.5 (53–76) |
61.5 (38.5-75.5) |
P = 0.01 |
|
| High prevalence countrya |
35/92 (38.0) |
8/78 (10.3) |
5.4 (2.2–13.7) |
4.3 (1.6–11.6) |
| Pacific Islander |
10/92 (10.9) |
14/78 (17.9) |
0.6 (0.2–1.4) |
|
| NZ Maori |
2/92 (2.2) |
6/78 (7.7) |
0.3 (0.04–1.5) |
|
| LTCF residence |
11/92 (12.0) |
8/78 (10.3) |
1.2 (0.4–3.5) |
|
| Community acquisitiona |
35/92 (38.0) |
6/78 (7.7) |
7.4 (2.7–21.1) |
7.9 (2.6–23.9) |
| Community onset infection |
73/92 (79.3) |
37/78 (47.4) |
4.3 (2.1–8.8) |
|
| Recent ICU admissiona |
5/92 (5.4) |
14/78 (17.9) |
0.3 (0.08–0.8) |
|
| Median hospital days (IQR) |
1.5 (0–16) |
9.5 (0–30.5) |
P <0.0001 |
|
| Hospital 1a |
53/92 (57.6) |
29/78 (37.1) |
2.3 (1.2–4.5) |
|
| Hospital 2a |
21/92 (22.8) |
32/78 (41.0) |
0.4 (0.2–0.9) |
0.3 (0.1–0.7) |
| Hospital 3a |
18/92 (19.6) |
17/78 (21.8) |
0.9 (0.4–2.0) |
|
|
Source of bacteraemia | ||||
| Urinary tract |
49/92 (53.3) |
33/78 (42.3) |
1.6 (0.8–3.0) |
|
| Gastrointestinal |
17/92 (18.5) |
10/78 (12.8) |
1.5 (0.6–3.9) |
|
| Central line |
0/92 (1.1) |
5/78 (7.7) |
P = 0.02 |
|
| Febrile neutropenia |
6/92 (5.4) |
13/78 (15.4) |
0.3 (0.1–1.1) |
|
| Prostate biopsy related |
8/92 (8.7) |
0/78 (0) |
P = 0.008 |
|
| Bone and joint |
0/92 (0) |
3/78 (3.8) |
P = 0.095 |
|
| Respiratory tract |
6/92(6.5) |
3/78 (3.8) |
1.7 (0.4–9.2) |
|
| Uncertainc |
4/92 (4.3) |
9/78 (11.5) |
0.3 (0.1–1.3) |
|
|
Comorbidities | ||||
| Diabetes |
22/92 (23.9) |
14/78 (17.9) |
1.4 (0.6–3.3) |
|
| Recurrent UTI |
4/92 (4.3) |
5/78 (6.4) |
0.7 (0.1–3.0) |
|
| Long term IDC |
11/92 (12.0) |
12/78 (15.4) |
0.7 (0.3–2.0) |
|
| Solid tumour |
17/92 (18.5) |
13/78 (16.7) |
1.1 (0.5–2.7) |
|
| Haematological malignancy |
12/92 (13.0) |
16/78 (20.5) |
0.6 (0.2–1.4) |
|
| Previous transplanta,b |
1/92 (1.1) |
7/78 (9.0) |
0.1 (0.005–0.9) |
0.06 (0.007–0.6) |
| Dialysis |
4/92 (4.3) |
2/78 (2.6) |
1.7 (0.3–14.0) |
|
| CPDa |
14/92 (15.2) |
4/78 (5.1) |
3.3 (1.0–12.6) |
5.5 (1.5–20.1) |
| Median number comorbidities (IQR) | 1 (1–3) | 1 (1–2) | P = 0.39 | |
aIndicates that variable was included in the multivariate analysis.
b4 patients with liver transplants, and 4 patients with hematopoietic stem cell transplants transplants (one additional patient with a liver transplant had separate episodes of ESBL-EC and ESBL-KP bacteremia).
cUncertain sources were those where the treating clinician was unable determine the aetiology.
dP values are included in this column for continuous variables and dichotomous variables for which an OR could not be calculated.
IQR, interquartile range; LTCF, long term care facility; UTI, urinary tract infection; IDC, Indwelling urinary catheter; CPD, Chronic pulmonary disease.